Validation Study of Oncoliq Blood Test for Early Breast Cancer Detection in Women Aged 40 to 70

What this Trial Is About

Cancer remains a major global health challenge, with late diagnosis contributing to high mortality. Researchers are evaluating a panel of microRNAs miRNAs found in blood that may help detect breast cancer early. These miRNAs regulate gene expression and tumors release them into the bloodstream, making them potential biomarkers. The study aims to validate these miRNAs to develop a test for early breast cancer detection using liquid biopsy technology. Participants include women diagnosed with breast cancer before any surgery or treatment, and a cancer-free control group confirmed by breast imaging. Blood samples will be collected to isolate plasma for miRNA analysis. The study will focus on analytical validation of the biomarkers through RT-qPCR and seek to develop an algorithm to distinguish individuals with and without breast cancer. The study runs from October 2025 to February 2026. Participants will provide blood samples for testing and researchers will analyze these samples to validate the miRNA panel. The main goal is to enroll 300 participants between October and December 2025, followed by development of a machine learning algorithm from December 2025 to March 2026. Study involvement includes blood collection and imaging confirmation for controls. The trial is observational and does not involve treatment or intervention beyond sample collection.

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.